MRVI vs NTLA Stock Comparison
Compare MRVI and NTLA across AIQ Score, fundamentals, valuation, momentum, risk, analyst expectations and current market evidence.
What is the main difference between MRVI and NTLA?
MRVI leads the current stock comparison as Maravai LifeSciences Holdings, Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
Maravai LifeSciences Holdings, Inc. vs Intellia Therapeutics, Inc.
MRVI leads
MRVI leads by 1 AIQ points, primarily on Quality and Risk Resilience. Wall Street currently favors NTLA on target upside.
Fragile: 3 of 6 evidence groups support MRVI, and its current signal state is conflicted.
Maravai LifeSciences Holdings, Inc.
Intellia Therapeutics, Inc.
The Algovestiq AIQ Score currently favors MRVI over NTLA, 35 versus 34 as of Sep 11, 2026. MRVI's advantage is driven primarily by stronger quality and risk resilience, while NTLA holds the stronger momentum profile. MRVI also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors NTLA. 3 of 6 covered evidence groups favor MRVI today, and the comparison is rated Fragile on stability: the AIQ gap is narrow at 1 points. MRVI lead: Stable — the AIQ differential has held near 1 points over 30 sessions.
Compare Maravai LifeSciences Holdings, Inc. and Intellia Therapeutics, Inc. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price-return comparison using available daily close history.
Total return comparison
Growth of $10,000
Based on available close-price history. Distribution reinvestment is not added unless already reflected in the source series.
Compare MRVI and NTLA against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality33 vs 28MRVI +5
- Momentum31 vs 35NTLA +4
- Risk Resilience46 vs 42MRVI +4
- Value34 vs 34Even
3 of 6 evidence groups favor MRVI. MRVI’s edge is concentrated in quality and risk resilience; NTLA keeps a meaningful momentum edge.
What changed since the last close
Latest scored session 2026-09-10, compared against the prior scored session 2026-09-09.
Largest factor move: Momentum -28
New signals
- RSI Oversold - Potential Bounce — bullish, momentum, short horizon
Largest factor move: Momentum +4
No new signals fired.
MRVI's lead narrowed by 8 AIQ points in the latest snapshot.
Deeper signal detail for each name lives on its own signals page — MRVI and NTLA both carry a full feed there.
The central trade-off
MRVI (Maravai LifeSciences Holdings, Inc.): the stronger current systematic profile, led by quality and risk resilience.
NTLA (Intellia Therapeutics, Inc.): the counter-case, on momentum, analyst expectations.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
MRVIMRVI on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
NTLANTLA on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
NTLANTLA on the Momentum factor, by 4 points.
Lower downside
MRVIMRVI on Risk Resilience, by 4 points.
Analyst upside
NTLANTLA on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors MRVI, analyst targets favor NTLA. That disagreement is the most useful thing on this page.
| Measure | MRVI | NTLA | Note |
|---|---|---|---|
| Implied upside to target | -8.1% | +99.3% | NTLA has more room |
| Target dispersion | 0% | +170.9% | Lower is tighter analyst agreement |
| Consensus | Buy | Hold | Context, not a primary driver |
| Analysts covering | 1 | 10 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 6 covered evidence groups favor MRVI. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | Even | 35 vs 34 |
| Fundamentals | MRVIon balance | revenue growth -21.9% vs -49.1%; EPS growth -213.7% vs 1.2%; TTM ROE -35.4% vs -57.8%; gross margin 34.6% vs -46.5%; operating margin 46% vs -7.1% — MRVI takes 4 of 5 decided legs, not all of them |
| Valuation | Even | Value 34 vs 34 |
| Technicals | MRVI | Price vs 50-day -4.3% vs -7.2%; vs 200-day 47.7% vs -5.4% |
| Risk Resilience | MRVI | Risk Resilience 46 vs 42 |
| Analyst expectations | NTLA | Target upside -8.1% vs 99.3% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of MRVI and NTLA and are excluded from the count.
AIQ Decision Stability
The conclusion is sensitive to small changes. Treat the lead as provisional and watch the flip conditions below.
- The AIQ gap is narrow at 1 points. (argues the conclusion is provisional)
- Only 3 of 6 covered evidence groups agree. (argues the conclusion is provisional)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on MRVI.
How the comparison changed
119 daily snapshots · May 4 – Sep 10MRVI lead: Stable — the AIQ differential has held near 1 points over 30 sessions.
- Today
- MRVI +1
- 35 vs 34
- 7 sessions ago
- MRVI +8
- 46 vs 38
- 30 sessions ago
- MRVI +3
- 44 vs 41
- 90 sessions ago
- MRVI +2
- 47 vs 45
The lead changed hands 2 times in this window, most recently on Aug 19 when MRVI moved ahead of NTLA.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
3 bullish / 1 bearish / 2 neutral, conflicted
- Golden Cross Active — bullish, trend, long horizon (49.81%)
- Bollinger Band Squeeze — neutral, volatility, short horizon
- RSI Oversold - Potential Bounce — bullish, momentum, short horizon
1 bullish / 1 bearish / 2 neutral, conflicted
- Golden Cross Active — bullish, trend, long horizon (0.34%)
- Bollinger Band Squeeze — neutral, volatility, short horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (5.50%)
MRVI leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price and the AIQ Score both moved down over the latest session (price -2.97%, AIQ -7 points).
Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -1.59%, AIQ +1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1NTLA closes the Quality gap — currently 5 points behind, the largest single contributor to MRVI's edge.
- 2NTLA's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend.
- 3MRVI's conflicting signal state resolves bearish — it currently carries 3 bullish and 1 bearish rules at once.
- 4A regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
MRVI leads on balance| Metric | MRVI | NTLA |
|---|---|---|
| Revenue growth (YoY) | -21.9% | -49.1% |
| EPS growth (YoY) | -213.7% | 1.2% |
| Gross margin | 34.6% | -46.5% |
| Operating margin | 46% | -7.1% |
| Return on equity (TTM) | -35.4% | -57.8% |
| Debt to equity | 0.86 | 0.1 |
Performance
MRVI leads 5 of 6 windows| Metric | MRVI | NTLA |
|---|---|---|
| 1 week (5 sessions) | -8.8% | -6.5% |
| 1 month (20 sessions) | 16.4% | -1.3% |
| 3 months (63 sessions) | 32.5% | -2.2% |
| 6 months (126 sessions) | 89.6% | -8.3% |
| Year to date | 107.1% | 32.7% |
| 1 year (252 sessions) | 175.8% | 0.8% |
Technicals
MRVI has the stronger structure| Metric | MRVI | NTLA |
|---|---|---|
| RSI (14) | 28.1 | 42.7 |
| ADX (14) | 25.8 | 14.4 |
| Price vs 50-day | -4.3% | -7.2% |
| Price vs 200-day | 47.7% | -5.4% |
| Volatility (1M, annualized) | 120.1% | 71% |
Risk
MRVI is the more resilient| Metric | MRVI | NTLA |
|---|---|---|
| Beta | 1.3 | 2.28 |
| Sharpe ratio | 1.63 | 0.5 |
| Sortino ratio | 3.27 | 0.64 |
| Max drawdown | -29.6% | -71.3% |
| Current drawdown | -25.2% | -57.4% |
| Annualized volatility | 68.4% | 100.5% |
| Value at risk (95%) | -6% | -8.1% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, MRVI or NTLA?
On the Algovestiq AIQ Score, MRVI is the stronger of the two as of Sep 11, 2026, scoring 35 against NTLA's 34. The edge comes from quality and risk resilience. NTLA is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is MRVI or NTLA the better buy right now?
MRVI carries the stronger systematic profile as of Sep 11, 2026, and the comparison is rated Fragile — 3 of 6 covered evidence groups agree. A Fragile rating means the conclusion is sensitive: the AIQ gap is narrow at 1 points. Treat the lead as provisional.
Why does the AIQ Score favor MRVI over NTLA?
The composite weights Quality, Value, Momentum and Risk Resilience. MRVI leads Quality by 5 points; NTLA leads Momentum by 4 points; MRVI leads Risk Resilience by 4 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, MRVI or NTLA?
Analyst price targets imply -8.1% upside for MRVI and +99.3% for NTLA, so the Street currently favors NTLA. That points the opposite way to the AIQ Score, which favors MRVI. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, MRVI or NTLA?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, MRVI or NTLA?
NTLA on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, MRVI or NTLA?
NTLA on the Momentum factor, by 4 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, MRVI or NTLA?
MRVI is the more resilient of the two, so the other name carries the higher downside risk. MRVI on Risk Resilience, by 4 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is MRVI more profitable than NTLA?
MRVI leads on the comparable margin measures — gross margin 34.6% vs -46.5%; operating margin 46% vs -7.1%; ttm roe -35.4% vs -57.8%.
Is MRVI's lead over NTLA getting stronger or weaker?
MRVI lead: Stable — the AIQ differential has held near 1 points over 30 sessions. This is measured from 119 daily comparison snapshots between 2026-05-04 and 2026-09-10. The lead has changed hands 2 times in that window, most recently on 2026-08-19, when MRVI moved ahead of NTLA.
What would change the MRVI vs NTLA verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: NTLA closes the Quality gap — currently 5 points behind, the largest single contributor to MRVI's edge; NTLA's Bollinger Band Squeeze turns directional — it is neutral today and would confirm a change in trend; MRVI's conflicting signal state resolves bearish — it currently carries 3 bullish and 1 bearish rules at once; a regime shift changes factor weighting — Quality and Value carry the heaviest weights in the composite, so a rotation toward either would move the result most.
What do the current signals say about MRVI and NTLA?
MRVI: 3 bullish / 1 bearish / 2 neutral, conflicted. NTLA: 1 bullish / 1 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on MRVI is Golden Cross Active (bullish, long horizon). On NTLA it is Golden Cross Active (bullish, long horizon).
Compare MRVI and NTLA with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.